Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $263.38 USD
Change Today +0.13 / 0.05%
Volume 1.5M
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc-adr (SHPG) Snapshot

Open
$265.87
Previous Close
$263.25
Day High
$270.63
Day Low
$263.06
52 Week High
07/29/15 - $270.63
52 Week Low
10/15/14 - $156.25
Market Cap
52.0B
Average Volume 10 Days
813.8K
EPS TTM
--
Shares Outstanding
197.3M
EX-Date
03/11/15
P/E TM
--
Dividend
$1.15
Dividend Yield
0.26%
Current Stock Chart for SHIRE PLC-ADR (SHPG)

shire plc-adr (SHPG) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc-adr (SHPG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc-adr (SHPG) Key Developments

Shire plc Announces Interim Dividend

The board of Shire plc has approved an interim dividend of USD 4.21 per ordinary share, up from USD 3.83 a year earlier.

Shire plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the 2015 and 2016; Reports Impairment Charges for the Second Quarter Ended June 30, 2015

Shire plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the period, the company reported total revenues of $1,557.6 million against $1,502.1 million for the same period in the last year. Operating income from continuing operations was $132.6 million against $337.9 million for the same period in the last year. Income from continuing operations before income taxes and equity in losses of equity method investees was $119.9 million against $348.8 million for the same period in the last year. Income from continuing operations, net of tax was $164.1 million against $528.3 million a year ago. Net income was $159.6 million against $523.1 million for the same period in the last year. Non GAAP diluted earnings per American Depository share were $2.63 against $2.67 a year ago. US GAAP basis diluted earnings per ADS were $0.81 against $2.66 a year ago. Net cash provided by operating activities was $452.3 million against $834.0 a year ago. Net debt, Non GAAP measure, at June 30, 2015 was $2,253.4 million against $2,118.7, at December 31, 2014. Purchases of non-current investments were $2.4 million against $2.8 million for the same period in the last year. Purchases of PP&E were $20.5 million against $3.8 million for the same period in the last year. Non GAAP EBITDA was $653.9 million against $674.9 million for the same period in the last year. Non-GAAP operating income from continuing operations was $614.0 million against $630.2 million for the same period in the last year. Non GAAP cash generation was $505.3 million against $658.6 million a year ago. Capital expenditure was $20.5 million against $3.8 million a year ago. The company ended the quarter with net debt of $2.25 billion. For the six months, the company reported total revenues of $3,046.0 million against $2,848.9 million for the same period in the last year. Operating income from continuing operations was $607.2 million against $644.8 million for the same period in the last year. Income from continuing operations before income taxes and equity in losses of equity method investees was $591.2 million against $653.1 million for the same period in the last year. Income from continuing operations, net of tax was $577.0 million against $781.4 million a year ago. Net income was $570.0 million against $753.5 million for the same period in the last year. Purchases of non-current investments were $4.9 million against $3.1 million for the same period in the last year. Purchases of PP&E were $39.8 million against $19.1 million for the same period in the last year. Non GAAP EBITDA was $1,368.8 million against $1,302.5 million for the same period in the last year. Non-GAAP operating income from continuing operations was $1,296.6 million against $1,221.0 million for the same period in the last year. Non GAAP cash generation was $1,021.1 million against $989.9 million a year ago. Net cash provided by operating activities was $1,013.9 million against $1,080.1 a year ago. Capital expenditure was $39.8 million against $19.1 million a year ago. For the quarter, impairment of IPR&D intangible assets were $523.3 million compared to $22.0 million a year ago. Non GAAP diluted earnings per ADS growth guidance increased to mid-to-high single digit % range for the full year 2015. The company expects to meet its 10x20 target of $6.5 billion of product sales in 2016, and exceed it with the contribution from its recent acquisition of NPS. For the year 2015, the company still expects its effective tax rate on non-GAAP income to be in the range of 15% to 17% before reverting to the 17% to 19% range in 2016 and beyond. The company expects non-GAAP net interest and other expense to remain in line with 2014 levels. Non-GAAP gross margin is still expected to be similar to 2014 levels.

Shire plc Reports Positive Top-Line Results from 39-Week, Long-Term Maintenance of Efficacy Study of Vyvanse

Shire plc reported positive top-line results from a 39-week, long-term maintenance of efficacy study of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) in adults with moderate to severe Binge Eating Disorder (B.E.D.). The objective of the study was to evaluate the maintenance of efficacy between Vyvanse and placebo, based on the primary endpoint of time to relapse of binge eating symptoms in adults (aged 18 to 55) with moderate to severe B.E.D. During the 26-week, double-blind, randomized-withdrawal phase of the study, Vyvanse demonstrated superiority over placebo. This Phase 3, 39-week, multi-center, placebo-controlled, double-blind, dose-optimized, randomized-withdrawal design study evaluated the maintenance of efficacy between Vyvanse and placebo based on the primary endpoint of time to relapse of binge eating symptoms in adults with moderate to severe B.E.D. (N= 418) based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision (DSM-IV-TR®) criteria. The study consisted of a 4-week screening period, a 12-week open-label treatment phase (4 weeks of dose optimization and 8 weeks of maintenance), followed by a 26-week, double-blind, randomized-withdrawal phase and a follow-up visit one week after the last on-treatment visit. During the dose-optimization period, all Vyvanse-treated patients were initiated at the 30-mg dose, and then titrated in 20-mg increments to their optimal dose (either 50-mg or 70-mg). Patients who met response criteria (one or fewer binge days each week for four consecutive weeks prior to the last visit at the end of the 12-week open-label phase and had a Clinical Global Impression-Severity [CGI-S] score of two or less at the same visit) were randomized to Vyvanse or placebo treatment groups. During this randomized-withdrawal phase, patients (N=275) received either ongoing treatment with the same optimized dose of Vyvanse from the open-label phase (N=137) or placebo (N=138). The primary endpoint was defined as the time to relapse of binge eating symptoms during the randomized phase. Relapse was defined as a two or more point increase (worsening) in the investigator's assessment of CGI-S score from the randomization baseline and two or more binge eating days per week in each week for two consecutive weeks prior to the visit. Vyvanse demonstrated superiority over placebo (pStudy SPD489-345 This Phase 3, 53-week, multi-center, open-label extension, dose-optimized study was designed to assess the safety and tolerability of Vyvanse in adults with moderate to severe B.E.D. based on DSM-IV-TR® criteria (N=604). Subjects enrolled were from previously completed double-blind, placebo-controlled studies. The study consisted of a 4-week dose-optimization period, a 48-week maintenance period, and a follow-up visit 1 week after the last on-treatment visit. Safety and tolerability evaluations included TEAEs, response to the Columbia-Suicide Severity Rating Scale (C-SSRS), vital signs, weight and waist circumference, clinical laboratory evaluations, and electrocardiogram (ECG) results. During the 52-week open-label treatment phase, 17 patients treated with Vyvanse experienced SAEs and 54 patients on Vyvanse had TEAEs that led to study discontinuation. The most commonly reported TEAEs in patients taking Vyvanse (reported in 5% or more of patients) included dry mouth, headache, insomnia, upper respiratory tract infection, nasopharyngitis, constipation, nausea, decreased appetite, irritability, bruxism, sinusitis, anxiety and feeling jittery. The safety profile for Vyvanse in this study was generally consistent with that currently outlined in the United States Prescribing Information (USPI). Shire anticipates presenting the data from studies SPD489-346 and SPD489-345 at future scientific meetings.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $263.38 USD +0.13

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Inc $313.34 USD -6.59
CSL Ltd A$96.35 AUD -1.35
Eisai Co Ltd ¥8,084 JPY -42.00
Mylan NV $57.24 USD +0.89
Perrigo Co PLC $192.83 USD +0.76
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 16.8x
Price/Sales 8.3x
Price/Book 5.7x
Price/Cash Flow 16.1x
TEV/Sales 8.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.